AstraZeneca is reportedly in talks over a major merger with Bristol Myers SquibbAstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. Reports indicated that a deal could develop further in the near future but “may be delayed or fall apart”, according to sources. Bristol Myers Squibb (BMS) has been contacted for comment. Cambridge-based AstraZeneca is the UK’s second most valuable company, with a market value of around £196 billion prior to the reports. A move comes amid efforts from AstraZeneca to grow its foothold in the US under boss Pascal Soriot.